Angiogenesis conference set for September

- Last updated on GMT

Related tags: Drug development

A conference examining the progress made in the field of
angiogenesis inhibition,organised by SRI, will take place 29-30
September in Cambridge, Massachusetts.

A conference examining the progress made in the field of angiogenesis inhibition will take place 29-30 September in Cambridge, Massachusetts, according to the organiser, Strategic Research Institute.

The development of angiogenesis inhibitors as potential treatments for cancer - i.e. inhibiting growth of a tumour by disrupting the blood vessels that supply it - has been ongoing for more than a decade, but it is only recently that candidate drugs have made it through to late-stage clinical trials.

SRI's conference, entitled Angiogenesis: New Opportunities & Solutions for Drug Development, will showcase a range of antiangiogenic therapeutic drugs, present work on the current development of agents showing the greatest clinical potential, and discuss new challenges in successful drug development.

The opening keynote speaker at the event will be Judah Folkman of Harvard Medical School and Boston Children's Hospital, whose laboratory is credited with developing endostatin, an anti-angiogenic agent licensed to US company EntreMed. World-reknowned DNA scientist James Watson of Cold Spring Harbor Laboratory in the USA will close the conference.

Additional information on the conference can be obtained from SRI​.

Related topics: Preclinical Research

Related news

Follow us

Products

View more

Webinars